UK Science Budget: Research Councils Receive Largest Real-Terms Increase in a Decade
UK Research and Innovation, the umbrella body responsible for public research funding across universities and research institutes in the United Kingdom, received its largest real-terms budget increase in over a decade in the comprehensive spending review settlement. The uplift, welcomed by the scientific community as a signal of genuine governmental commitment to the role of research and development as a driver of long-term economic growth, reversed a period of relative stagnation in public science spending that had been a source of concern for academic leaders and business groups alike.
The seven research councils that make up UKRI — spanning natural science, engineering, social science, medical research and the arts and humanities — each received meaningful increases in their grant funding budgets, enabling them to expand the number of research grants awarded and to invest in major infrastructure projects that had been waiting for capital availability. The Medical Research Council, which funds clinical and biomedical research with direct health relevance, saw particular emphasis in the settlement, reflecting the government’s stated commitment to making the UK a global leader in life sciences and health innovation.
University vice-chancellors and research directors expressed genuine relief at the settlement, noting that the combination of frozen tuition fee income and constrained grant budgets had been creating serious financial pressure at many institutions, with research activity in some cases having to be sustained through cross-subsidy from international student fee income — a model vulnerable to geopolitical and regulatory changes affecting international student recruitment.
The government’s Innovate UK arm, which funds applied research with commercial application potential, also received increased resources to accelerate the translation of publicly funded research discoveries into commercial products and companies — a key priority given the persistent gap between the UK’s strong academic research performance and its relative underperformance in commercialising discoveries.
